Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
[HTML][HTML] Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual …
Objective There is a need to develop and validate biomarkers for treatment response and
survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response …
survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response …
[HTML][HTML] ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …
The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
Cancer of the ovary, fallopian tube, and peritoneum
JS Berek, ST Kehoe, L Kumar… - International journal of …, 2018 - Wiley Online Library
Abstract The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of
ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same …
ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same …
Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer
NM De Lange, NPM Ezendam, JS Kwon, I Vandenput… - Current …, 2019 - mdpi.com
Background: Data showing the value of neoadjuvant chemotherapy (NACT) followed by
interval debulking surgery (IDS) in the management of advanced-stage serous endometrial …
interval debulking surgery (IDS) in the management of advanced-stage serous endometrial …
Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)
HM Ditzel, KC Strickland, EE Meserve… - International Journal …, 2019 - journals.lww.com
A chemotherapy response score (CRS) system was recently described to assess the
histopathologic response and prognosis of patients with tubo-ovarian high-grade serous …
histopathologic response and prognosis of patients with tubo-ovarian high-grade serous …
Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: the prognostic role of omental and ovarian residual disease
Background: The chemotherapy response score (CRS) has emerged as a simple and
reproducible histopathological grading system for assessing chemotherapy response in …
reproducible histopathological grading system for assessing chemotherapy response in …
Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
M Liontos, A Andrikopoulou, K Koutsoukos… - Journal of ovarian …, 2021 - Springer
Background Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery
(IDS) is the recommended approach in patients with advanced epithelial ovarian cancer …
(IDS) is the recommended approach in patients with advanced epithelial ovarian cancer …
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
S Betrian, MA Angeles, AG Moreno, B Cabarrou… - International Journal of …, 2022 - Elsevier
Objective We sought to evaluate the impact of chemotherapy response score according to
the number of cycles of neoadjuvant chemotherapy, on disease-free survival and overall …
the number of cycles of neoadjuvant chemotherapy, on disease-free survival and overall …
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
RD Morgan, X Wang, BM Barnes, L Spurgeon… - British Journal of …, 2024 - nature.com
Background High-grade serous ovarian cancer (HGSOC) can be treated with platinum-
based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS) …
based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS) …